IP Verse

Pharmaceutical Formulations Containing Rifaximin, Processes For Their Obtainment And Method Of Treating Intestinal Disease - EP2618819

The patent EP2618819 was granted to Alfasigma on Nov 1, 2017. The application was originally filed on Sep 21, 2011 under application number EP11776879A. The patent is currently recorded with a legal status of "Revoked".

EP2618819

ALFASIGMA
Application Number
EP11776879A
Filing Date
Sep 21, 2011
Status
Revoked
Oct 17, 2022
Grant Date
Nov 1, 2017
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

SANDOZJul 31, 2018TER MEER STEINMEISTER & PARTNER -

Patent Citations (24) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONIT1362820
DESCRIPTIONUS2008132530
DESCRIPTIONUS2008262024
DESCRIPTIONUS2008262220
DESCRIPTIONUS2009011020
DESCRIPTIONUS2009082558
DESCRIPTIONUS2009130201
DESCRIPTIONUS2010010028
DESCRIPTIONUS7045620
DESCRIPTIONWO2005044823
DESCRIPTIONWO2006094662
DESCRIPTIONWO2006094737
DESCRIPTIONWO2008029208
DESCRIPTIONWO2008035108
DESCRIPTIONWO2008155728
DESCRIPTIONWO2009108730
INTERNATIONAL-SEARCH-REPORTUS2005101598
INTERNATIONAL-SEARCH-REPORTUS2008262012
INTERNATIONAL-SEARCH-REPORTWO2006094737
INTERNATIONAL-SEARCH-REPORTWO2008029208
INTERNATIONAL-SEARCH-REPORTWO2009008005
OPPOSITIONEP1557421
OPPOSITIONWO2006094737
OPPOSITIONWO2008029208

Non-Patent Literature (NPL) Citations (3) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- G. C. VISCOMI et al., "Crystal forms of rifaximin and their effect on pharmaceutical properties", CrystEngComm, (20080000), vol. 10, pages 1074 - 1081, XP009152378
OPPOSITION- C. PRANTERA et al., "Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn's disease", Gastroenterology, (20120300), vol. 142, no. 3, pages 473 - 481, XP055122672
OPPOSITION- C. PRANTERA et al., "Antibiotic treatment of Crohn's disease: results of a multicenter double blind, randomized, placebo-controlled trial with rifaximin", Aliment. Pharmacol. Ther., (20060415), vol. 23, no. 8, pages 1117 - 1125, XP055509563

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents